Crispr Therapeutics AG (CRSP) Stock Price Today
Aura AI Summary
Key Stats
- $5.54BMarket Cap
- 2,995,890Volume
- HealthSector
- $76.7852W High
- $44.3452W Low
- 76 DaysTypical Hold Time
- $3.96BEnterprise Value
- -Div Yield
- 11% Sell | 89% BuyTrading Activity
Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Most Recent News
On Holding enters football market with Kylian Mbappé partnership, shares volatile despite 'Underperform' rating.
On Holding, a Swiss athletic shoe company, is expanding into the global football market by partnering with soccer star Kylian Mbappé, who leaves Nike after nearly 20 years. This marks On Holding's first venture into football cleats and apparel, lever...
Peter Thiel's fund re-enters market with $419M, heavily investing 72% in energy and power sectors.
Peter Thiel's investment fund, which held no stocks for two consecutive quarters, has made a significant comeback with $419 million in new investments. Notably, 72% of this capital has been allocated to the energy and power sectors, signaling a strat...
Vanguard FTSE All-World ex-US ETF offers strong value with 12.5x P/E and 8% earnings yield, supported by AI-driven growth in Asia.
The Vanguard FTSE All-World ex-US ETF (VEU) currently trades at a compelling valuation of about 12.5 times price-to-earnings with an 8% earnings yield, outperforming the SPY year-to-date despite a stronger dollar. Its broad diversification, solid mom...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.